Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.

DFMO may help control hair growth and treat cancer.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

JAK inhibitors might help treat alopecia areata.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

Oral valganciclovir improved a patient's skin condition caused by immunosuppression.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

New cytokine-targeted therapies show promise for treating alopecia areata.

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

PPAR-γ may be a key target for treating alopecia areata and other skin conditions.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Two women lost hair after mesotherapy for hair loss, with one having permanent and the other temporary hair loss.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Immunoadsorption successfully treated a man's resistant polymyositis.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

A blood pressure drug, diltiazem, may also help treat influenza.

Injectable platelet-rich fibrin (I-PRF) is more effective than platelet-rich plasma (PRP) for treating hair loss.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.